Key Figures

Key Figures for the First Half and Second Quarter of 2018

  Group Bioprocess Solutions Lab Products & Services
in millions of € unless otherwise specified 6-mo. 2018 6-mo. 2017 1) Δ in %
reported
Δ in % cc 2) 6-mo. 2018 6-mo. 2017 1) Δ in %
reported
Δ in % cc 2) 6-mo. 2018 6-mo. 2017 1) Δ in %
reported
Δ in % cc 2)
Sales Revenue and Order Intake
Sales revenue  758.4 702.5 8.0 11.9 550.3 510.1 7.9 11.9 208.1 192.4 8.1 12.0
- EMEA3) 324.4 301.8 7.5 8.4 229.5 208.5 10.0 10.7 94.9 93.3 1.8 3.3
- Americas3) 249.6 228.5 9.3 16.6 195.8 181.3 8.0 15.4 53.9 47.2 14.1 20.9
- Asia | Pacific3) 184.4 172.2 7.1 12.2 125.1 120.3 4.0 8.9 59.3 51.9 14.2 19.9
Order intake 807.6 741.9 8.9 12.7 594.6 546.9 8.7 12.6 213.0 195.0 9.2 13.1
Results         
EBITDA4) 189.5 172.9 9.6   153.9 140.0 10.0   35.5 33.0 7.8  
EBITDA margin4) in % 25.0 24.6   28.0 27.4   17.1 17.1  
Net result5) 79.8 69.9 14.1              
Financial data per share
Earnings per ordinary share5) in € 1.16 1.02 14.1              
Earnings per preference share5) in € 1.17 1.03 14.0              
30.06.2018 31.12.2017
Balance Sheet | Financials
Balance sheet total 2,418.62,297.7
Equity 845.2806.6
Equity ratio in % 34.935.1
Net debt 955.3895.5
Net debt | underlying EBITDA 2.62.5
Group Bioprocess Solutions Lab Products & Services
in millions of € unless otherwise specified  Q2
2018 6)
Q2
2017 1),6)
Δ in %
reported
Δ in % cc Q2
2018 6)
Q2
2017 1), 6)
Δ in %
reported
Δ in % cc Q2
2018 6)
Q2
2017 1), 6)
Δ in %
reported
Δ in % cc
Sales Revenue and Order Intake
Order intake 402.8 365.0 10.4 13.0 299.4 263.4 13.7 16.4 103.4 101.6 1.8 4.3
Sales revenue 393.5 359.4 9.5 12.4 286.9 258.9 10.8 13.8 106.6 100.4 6.2 8.9
Results
EBITDA4) 100.9 88.3 14.2   83.6 71.6 16.8   17.2 16.7 3.1  
EBITDA margin4) in % 25.6 24.6   29.2 27.7   16.1 16.6  
Net result5) 42.6 35.5 19.9              
Financial data per share
Earnings per ord. share 5) in € 0.62 0.52 19.9              
Earnings per pref. share 5) in € 0.62 0.52 19.9              

1) The previous year's figures have been restated due to the finalization of the purchase price allocations for the acquisitions of 2017

2) In constant currencies

3) Acc. to customers' location

4) Adjusted for extraordinary items

5) After non-controlling interest, adjusted for extraordinary items as well as non-cash amortization, and based on the normalized financial result as well as the corresponding tax effects for each of these items

6) Figures have not been audited or reviewed